152 related articles for article (PubMed ID: 17576064)
1. Benzo[b]thiophene-based histone deacetylase inhibitors.
Witter DJ; Belvedere S; Chen L; Secrist JP; Mosley RT; Miller TA
Bioorg Med Chem Lett; 2007 Aug; 17(16):4562-7. PubMed ID: 17576064
[TBL] [Abstract][Full Text] [Related]
2. Design and campaign synthesis of pyridine-based histone deacetylase inhibitors.
Andrews DM; Gibson KM; Graham MA; Matusiak ZS; Roberts CA; Stokes ES; Brady MC; Chresta CM
Bioorg Med Chem Lett; 2008 Apr; 18(8):2525-9. PubMed ID: 18378451
[TBL] [Abstract][Full Text] [Related]
3. Studies of the metabolic stability in cells of 5-(trifluoroacetyl)thiophene-2-carboxamides and identification of more stable class II histone deacetylase (HDAC) inhibitors.
Scarpelli R; Di Marco A; Ferrigno F; Laufer R; Marcucci I; Muraglia E; Ontoria JM; Rowley M; Serafini S; Steinkühler C; Jones P
Bioorg Med Chem Lett; 2008 Dec; 18(23):6078-82. PubMed ID: 18952417
[TBL] [Abstract][Full Text] [Related]
4. 2-Trifluoroacetylthiophene oxadiazoles as potent and selective class II human histone deacetylase inhibitors.
Muraglia E; Altamura S; Branca D; Cecchetti O; Ferrigno F; Orsale MV; Palumbi MC; Rowley M; Scarpelli R; Steinkühler C; Jones P
Bioorg Med Chem Lett; 2008 Dec; 18(23):6083-7. PubMed ID: 18930398
[TBL] [Abstract][Full Text] [Related]
5. 2-Trifluoroacetylthiophenes, a novel series of potent and selective class II histone deacetylase inhibitors.
Jones P; Bottomley MJ; Carfí A; Cecchetti O; Ferrigno F; Lo Surdo P; Ontoria JM; Rowley M; Scarpelli R; Schultz-Fademrecht C; Steinkühler C
Bioorg Med Chem Lett; 2008 Jun; 18(11):3456-61. PubMed ID: 18440229
[TBL] [Abstract][Full Text] [Related]
6. Amino acid derivatives as histone deacetylase inhibitors.
Hubbs JL; Zhou H; Kral AM; Fleming JC; Dahlberg WK; Hughes BL; Middleton RE; Szewczak AA; Secrist JP; Miller TA
Bioorg Med Chem Lett; 2008 Jan; 18(1):34-8. PubMed ID: 18042381
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and structure-activity relationship of histone deacetylase (HDAC) inhibitors with triazole-linked cap group.
Chen PC; Patil V; Guerrant W; Green P; Oyelere AK
Bioorg Med Chem; 2008 May; 16(9):4839-53. PubMed ID: 18397827
[TBL] [Abstract][Full Text] [Related]
8. Structural origin of selectivity in class II-selective histone deacetylase inhibitors.
Estiu G; Greenberg E; Harrison CB; Kwiatkowski NP; Mazitschek R; Bradner JE; Wiest O
J Med Chem; 2008 May; 51(10):2898-906. PubMed ID: 18412327
[TBL] [Abstract][Full Text] [Related]
9. Exploration of the internal cavity of histone deacetylase (HDAC) with selective HDAC1/HDAC2 inhibitors (SHI-1:2).
Methot JL; Chakravarty PK; Chenard M; Close J; Cruz JC; Dahlberg WK; Fleming J; Hamblett CL; Hamill JE; Harrington P; Harsch A; Heidebrecht R; Hughes B; Jung J; Kenific CM; Kral AM; Meinke PT; Middleton RE; Ozerova N; Sloman DL; Stanton MG; Szewczak AA; Tyagarajan S; Witter DJ; Secrist JP; Miller TA
Bioorg Med Chem Lett; 2008 Feb; 18(3):973-8. PubMed ID: 18182289
[TBL] [Abstract][Full Text] [Related]
10. Design of chimeric histone deacetylase- and tyrosine kinase-inhibitors: a series of imatinib hybrides as potent inhibitors of wild-type and mutant BCR-ABL, PDGF-Rbeta, and histone deacetylases.
Mahboobi S; Dove S; Sellmer A; Winkler M; Eichhorn E; Pongratz H; Ciossek T; Baer T; Maier T; Beckers T
J Med Chem; 2009 Apr; 52(8):2265-79. PubMed ID: 19301902
[TBL] [Abstract][Full Text] [Related]
11. Investigation on the isoform selectivity of histone deacetylase inhibitors using chemical feature based pharmacophore and docking approaches.
Zhu Y; Li HF; Lu S; Zheng YX; Wu Z; Tang WF; Zhou X; Lu T
Eur J Med Chem; 2010 May; 45(5):1777-91. PubMed ID: 20153566
[TBL] [Abstract][Full Text] [Related]
12. Design and synthesis of thiazole-5-hydroxamic acids as novel histone deacetylase inhibitors.
Anandan SK; Ward JS; Brokx RD; Denny T; Bray MR; Patel DV; Xiao XY
Bioorg Med Chem Lett; 2007 Nov; 17(21):5995-9. PubMed ID: 17827005
[TBL] [Abstract][Full Text] [Related]
13. Alpha-mercaptoketone based histone deacetylase inhibitors.
Wash PL; Hoffman TZ; Wiley BM; Bonnefous C; Smith ND; Sertic MS; Lawrence CM; Symons KT; Nguyen PM; Lustig KD; Guo X; Annable T; Noble SA; Hager JH; Hassig CA; Malecha JW
Bioorg Med Chem Lett; 2008 Dec; 18(24):6482-5. PubMed ID: 18954984
[TBL] [Abstract][Full Text] [Related]
14. New pyrrole-based histone deacetylase inhibitors: binding mode, enzyme- and cell-based investigations.
Mai A; Valente S; Nebbioso A; Simeoni S; Ragno R; Massa S; Brosch G; De Bellis F; Manzo F; Altucci L
Int J Biochem Cell Biol; 2009 Jan; 41(1):235-47. PubMed ID: 18834955
[TBL] [Abstract][Full Text] [Related]
15. Identification of novel, selective, and stable inhibitors of class II histone deacetylases. Validation studies of the inhibition of the enzymatic activity of HDAC4 by small molecules as a novel approach for cancer therapy.
Ontoria JM; Altamura S; Di Marco A; Ferrigno F; Laufer R; Muraglia E; Palumbi MC; Rowley M; Scarpelli R; Schultz-Fademrecht C; Serafini S; Steinkühler C; Jones P
J Med Chem; 2009 Nov; 52(21):6782-9. PubMed ID: 19888759
[TBL] [Abstract][Full Text] [Related]
16. Comparative molecular dynamics simulations of histone deacetylase-like protein: binding modes and free energy analysis to hydroxamic acid inhibitors.
Yan C; Xiu Z; Li X; Li S; Hao C; Teng H
Proteins; 2008 Oct; 73(1):134-49. PubMed ID: 18398905
[TBL] [Abstract][Full Text] [Related]
17. Identification of (1H)-pyrroles as histone deacetylase inhibitors with antitumoral activity.
Zubia A; Ropero S; Otaegui D; Ballestar E; Fraga MF; Boix-Chornet M; Berdasco M; Martinez A; Coll-Mulet L; Gil J; Cossío FP; Esteller M
Oncogene; 2009 Mar; 28(11):1477-84. PubMed ID: 19169274
[TBL] [Abstract][Full Text] [Related]
18. Identification of novel small-molecule histone deacetylase inhibitors by medium-throughput screening using a fluorigenic assay.
Wegener D; Hildmann C; Riester D; Schober A; Meyer-Almes FJ; Deubzer HE; Oehme I; Witt O; Lang S; Jaensch M; Makarov V; Lange C; Busse B; Schwienhorst A
Biochem J; 2008 Jul; 413(1):143-50. PubMed ID: 18384290
[TBL] [Abstract][Full Text] [Related]
19. Dibasic benzo[b]thiophene derivatives as a novel class of active site-directed thrombin inhibitors. 1. Determination of the serine protease selectivity, structure-activity relationships, and binding orientation.
Sall DJ; Bastian JA; Briggs SL; Buben JA; Chirgadze NY; Clawson DK; Denney ML; Giera DD; Gifford-Moore DS; Harper RW; Hauser KL; Klimkowski VJ; Kohn TJ; Lin HS; McCowan JR; Palkowitz AD; Smith GF; Takeuchi K; Thrasher KJ; Tinsley JM; Utterback BG; Yan SC; Zhang M
J Med Chem; 1997 Oct; 40(22):3489-93. PubMed ID: 9357512
[No Abstract] [Full Text] [Related]
20. Optimization of biaryl Selective HDAC1&2 Inhibitors (SHI-1:2).
Witter DJ; Harrington P; Wilson KJ; Chenard M; Fleming JC; Haines B; Kral AM; Secrist JP; Miller TA
Bioorg Med Chem Lett; 2008 Jan; 18(2):726-31. PubMed ID: 18060775
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
